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Tbjective: Matrix metalloproteinase 9 plays an important role in the maintenance of
he aortic extracellular matrix. Genetic variations that affect protease expression or
ctivity might contribute to thoracic aortic disease. The purpose of this study was to
etermine whether 3 single nucleotide polymorphisms in the matrix metalloprotein-
se 9 gene are associated with thoracic aortic aneurysms and dissection.
ethods: Genomic DNA was isolated from blood or aortic tissue from 28 patients
ith degenerative thoracic aortic aneurysms, 60 patients with thoracic aortic dis-
ection, and 111 control patients. The frequency distributions of 3 matrix metallo-
roteinase 9 single nucleotide polymorphisms (8202A/G, IVS43G/T, and
003A/G [Q668R]) were determined by using genotyping accomplished with a
eal-time detection system. Associations between polymorphisms and disease were
stimated with odds ratios and their 95% confidence intervals.
esults: The frequency of the 8202G allele was significantly higher in patients
ith thoracic aortic aneurysms and aortic dissection (0.52 and 0.56, respectively)
han in control subjects (0.36, P  .001). Patients with thoracic aortic aneurysms or
issection were nearly 5 times more likely than control subjects to have the G allele
adjusted odds ratio, 4.87; 95% confidence interval, 2.04–11.64). There were no
ignificant associations between the IVS43G/T or 2003A/G polymorphisms and
horacic aortic disease.
onclusions: The matrix metalloproteinase 9 8202A/G polymorphism is associ-
ted with thoracic aortic aneurysms and dissection. Further studies are warranted to
lucidate the functional role of the –8202A/G variant in matrix metalloproteinase 9
xpression.
horacic aortic dissection (TAD) and degenerative thoracic aortic aneurysms
(TAAs) are major causes of mortality in the United States. Data from the
National Center for Health Statistics at the Centers for Disease Control and
revention reveal that aortic dissection and aneurysms rank among the 15 leading
auses of death for all Americans (all races, both sexes) between the ages of 55 and
4 years.1 Despite the lethality of these disease processes, their underlying mech-
nisms remain poorly understood.
The medial layer of the aorta is composed of vascular smooth muscle cells and
xtracellular matrix (ECM) proteins, primarily elastin and collagen. Maintaining a
alanced composition of vascular smooth muscle cells and ECM proteins appears to
e critical for preserving the important functional properties of the thoracic aorta,
specially its mechanical compliance with pulsatile blood flow. Disturbances in the
etabolic balance that result in excessive ECM degradation might lead to progres-ive aortic wall deterioration, expansion, and rupture.2
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 5 1045
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1
A
CDThe matrix metalloproteinases (MMPs) are a family of
ore than 20 zinc-dependent proteolytic enzymes.3-5 These
nzymes play vital roles in diseases related to ECM metab-
lism and aortic wall remodeling, which might be relevant
o the development of aneurysms or dissection.6,7 Recent
tudies have shown that excessive activation of one MMP,
MP-9, occurs in abdominal aortic aneurysms and might
ontribute to rapid aortic expansion and rupture.8,9 In-
reased MMP-9 expression has also been observed in pa-
ients with thoracic aortic disease.10-12
The genetic aspects of TAA and TAD remain relatively
nexplored, except in patients with connective tissue disor-
ers, such as the Marfan and Ehlers-Danlos syndromes, and
amilial syndromes caused by rare genetic mutations.13-15
ecause there is extensive literature about the role of
MP-9 in abdominal aortic aneurysms, the MMP-9 gene
MMP9) has emerged as a target for investigation in patients
ith thoracic aortic disease.
A single nucleotide polymorphism (SNP) is a common
ucleotide variant in DNA at a single nucleotide site. Each
ndividual has many SNPs that together create a unique
NA sequence. SNPs are highly conserved during evolu-
ion and within populations. They are thought to be the
ause of most human diseases that have a genetic compo-
ent or, at least, to be positional markers of disease genes.
number of MMP9 SNPs have been identified and re-
orded in the National Center for Biotechnology Informa-
ion dbSNP database. Some MMP9 SNPs have been asso-
iated with specific phenotypic features of breast cancers,
ith outcomes in patients with breast cancer, with invasive-
ess of gastric cancer, and with risk for coronary artery
isease.16-18 Although one SNP, found at 1562bp (ie, the
ucleotide that is 1562 base pairs away from the start of
ranscription) in the promoter region of MMP9, has been
ssociated with abdominal aortic aneurysms,19 the role of
MP9 polymorphisms in thoracic aortic disease is unknown.
The purpose of this case-control study was to examine
he association of 3 MMP9 SNPs with TAA and TAD in a
hite population. The 3 SNPs examined were 8202A/G
dbSNP ID: rs11697325) in the 5= untranscribed region,
VS43G/T (dbSNP ID: rs2274755) at the fourth intron,
nd 2003A/G (Q668R; dbSNP ID: rs2274756) at the twelfth
Abbreviations and Acronyms
ECM  extracellular matrix
MMPmatrix metalloproteinase
OR  odds ratio
PCR  polymerase chain reaction
SNP  single nucleotide polymorphism
TAA  thoracic aortic aneurysm
TAD  thoracic aortic dissectionxon. o
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atients
hree groups of patients were compared: 2 groups of patients with
horacic aortic disease and 1 group of control patients (Table 1).
he 2 disease groups consisted of patients undergoing treatment at
aylor College of Medicine for TAD (n  60) or degenerative
AA not caused by aortic dissection (n  28). Because the
requencies of SNPs vary among ethnic groups, we restricted our
tudy to white patients. Patients with Marfan syndrome, Ehlers-
anlos syndrome, traumatic aneurysms, or aortic coarctation were
xcluded from the study. The TAD group included 1 patient with
bicuspid aortic valve, 1 with giant cell arteritis, and 1 with aortic
upture. Fifty-nine patients had classic dissection, and 1 patient
ad an intramural hematoma. The TAA group included 1 patient
ith aortic rupture; there were no patients with pseudoaneurysms
r mycotic aneurysms in this group.
Although TAD and degenerative TAAs represent distinct dis-
ase processes, occasionally patients present with both conditions.
his occurs when either (1) a TAD is superimposed on a preex-
sting TAA or (2) a TAA exists isolated from a TAD. Three
atients had both TAD and degenerative TAA and therefore were
ncluded in both of the disease groups for this analysis. One of
hese patients had a degenerative thoracoabdominal aortic aneu-
ysm and had previously undergone ascending aortic repair for a
eBakey type II dissection. The other 2 patients had DeBakey type
II dissection (1 classic dissection and 1 intramural hematoma) and
nrepaired degenerative ascending aortic aneurysms.
The control group consisted of 111 white patients with chest
ain who visited the Eastern Heart Clinic in Australia for angio-
raphic examination. Control patients were enrolled only if an-
iography revealed no evidence of coronary artery disease, ascend-
ng aortic dissection, or abnormal ascending aortic diameter.
Informed consent was obtained from all patients. The genotype
nalysis of the control patients was approved by the Ethics Com-
ittee of the University of New South Wales, Sydney, Australia.
he patients with TAA and the patients with TAD were recruited
or this study under a protocol approved by the Institutional
eview Board at Baylor College of Medicine.
ample and Data Collection
lood samples were obtained from 161 patients (24 patients with
AA, 26 patients with TAD, and 111 control subjects), and tissue
amples were obtained from 35 patients (1 patient with TAA, 31
atients with TAD, and 3 patients with TAATAD). Blood was
ollected in 4-mL ethylenediamine tetraacetate tubes. Within 15
inutes of collection, blood was placed in storage at 80°C.
amples of aneurysmal or dissected aortic wall were collected
uring surgical repair; this tissue is routinely excised during the
peration and would normally be discarded. All tissue specimens
ere rinsed with sterile saline. Blood clots and adipose tissue were
emoved from the aortic samples. The samples were placed in
ryogenic vials and snap-frozen in liquid nitrogen for 1 minute.
he frozen samples were stored at 80°C until batch analysis was
erformed.
For each patient, a complete data sheet containing detailed
linical information was filled out at the time of sample collection.
atients were considered to have a positive family history of TAA
r TAD if they reported having any first-degree relative with these
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A
CDABLE 1. Demographic and clinical characteristics of the study groups
Variable
Group
TAA (n  28) TAD (n  60) Control (n  111)
Male sex 21 (75%) 46 (77%) 63 (57%)
Mean age  SD (y) 67.2 10.0 59.9 12.6 51.7  11.0
Age range (y) 42-81 22-81 17-80
Smoking history
None 5 (18%) 22 (37%) *
Current 10 (36%) 11 (18%) *
Past 13 (46%) 27 (45%) *
Previous cardiac-aortic surgery 7 (25%) 29 (48%) *
Coronary artery bypass 4 7 0
Aortic valve replacement 0 7 *
Ascending aorta 1 19 0
Aortic arch 1 6 *
Descending thoracic aorta 1 2 *
Abdominal aorta 2 1 *
Thoracoabdominal aorta 2 0 *
Taking lipid-lowering medication 19 (68%) 23 (38%) *
Family history of aneurysm 4 (14%) 4 (7%) *
Family history of dissection 0 3 (5%) *
Bicuspid aortic valve 0 1 (2%) *
Arteritis 0 1 (2%) *
Rupture 1 (4%) 1 (2%) NA
Location of degenerative aneurysm(s)
Aortic root 3 (11%) 0 NA
Ascending aorta 10 (36%) 2 (3%)† NA
Transverse aortic arch 6 (21%) 0 NA
Descending thoracic aorta 1 (4%) 0 NA
Thoracoabdominal aorta 17 (61%) 1 (2%)† NA
Acuity of dissection
Acute 2 (7%)† 13 (22%) NA
Chronic 1 (4%)† 47 (78%) NA
Extent of dissection
DeBakey type I 0 25 (42%) NA
DeBakey type II 1 (4%)† 11 (18%) NA
DeBakey type III 2 (7%)† 24 (40%) NA
Mean no. of segments involved  SD‡ 2.6 1.4 2.9  1.3 NA
Mean maximum aortic diameter  SD (cm) 6.2 1.3 6.1  1.4 *
Range of maximum aortic diameter (cm) 4.0-9.0 3.6-10.0 *
AA, Thoracic aortic aneurysm; TAD, thoracic aortic dissection; SD, standard deviation; NA, not applicable. *Not obtained. †Three patients had both
horacic aortic aneurysm and thoracic aortic dissection and are included in both groups. ‡Based on involvement of up to 5 aortic segments: ascending,
ransverse arch, descending thoracic, suprarenal abdominal, and infrarenal abdominal.ABLE 2. Single nucleotide polymorphism genotyping assay information
Reporter
NP VIC* FAM† Context sequence‡
8202A/G A G 5=GCCCAGCCCAGCCTGCAGCCCTGGG[A/G]CTCTGCAGCAGCACAGTCAGAAATG 3=
VS43G/T G T 5=GTGGTCCCTGGGCAAGGGCGTCGGT[G/T]AGATTCTGAGTCCTCCTGGCCCCTG 3=
003A/G (Q668R) A G 5=GACACGCACGACGTCTTCCAGTACC[A/G]AGGTGAGGGCTGAGGAGGATCCCTT 3=
NP, Single nucleotide polymorphiosm. *VIC dye used to label the TaqMan probe that detects the allele 1 sequence. †FAM dye used to label the TaqMan
robe that detects the allele 2 sequence. ‡Twenty-five nucleotides on both sides of the SNP site, which is indicated in brackets (ie, NNN[A1/A2]NNN,
here A1  allele 1 and A2  allele 2).
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 5 1047
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1
A
CDonditions. The maximum aortic diameter of each patient with
AA and TAD was measured from the patient’s most recent
omputed tomographic scan.
MP9 Genotyping
NAzol DNA extraction kits (Invitrogen, Carlsbad, Calif) were
sed to isolate genomic DNA from blood and aortic tissue. The
ssays-on-Demand TaqMan SNP Genotyping Assays (Applied
iosystems, Foster City, Calif) of 3 SNPs (Table 2) were used to
etermine MMP9 genotypes; each assay consisted of a 20 mix of
nlabeled polymerase chain reaction (PCR) primers and a TaqMan
inor groove binder probe. Primers were designed against a con-
erved region of the genome flanking the locus of interest. Two
robes were designed across the locus of interest, one for each
llele. Each probe was labeled with a different reporter dye, as well
s a quencher molecule. Proximity to the quencher dye inhibited
he fluorescence of the reporter molecule. During thermocycling,
he probe annealed to the locus of interest in an allele-specific
anner. As the Taq DNA polymerase extended the primers, it also
egraded the annealed probe, allowing the fluorescent dye to come
ut of the sphere of influence of the quencher and thus become
etectable. Genotyping was accomplished with the ICycler iQ
eal-Time Detection System (Bio-Rad Laboratories, Hercules,
alif). Allelic discrimination real-time PCR was accomplished
ith a 25-L reaction mixture containing 20 ng of DNA, 12.5 L
f TaqMan Universal PCR Master Mix (Applied Biosystems), and
.25 L of 20 TaqMan SNP Genotyping Assay Mix (Applied
iosystems). The PCR profile consisted of an initial melting step
ABLE 3. 8202A/G genotypes, their association with the r
nd G allele frequencies in patients and control subjects
enotype
Control subject
(n  111)
No. % No.
A 46 41.4 1
G 50 45.1 25
G 15 13.5 2
GGG 65 58.6 27
allele frequency 0.36
dds ratios and their 95% confidence intervals were calculated with logist
djusted for age and sex. TAA, Thoracic aortic aneurysm; TAD, thoracic
ABLE 4. IVS43G/T genotypes, their association with the
nd T allele frequencies in patients and control subjects
enotype
Control subjects
(n  111)
No. % No.
G 83 74.8 21
G 26 23.4 7
T 2 1.8 0
allele frequency 0.14
dds ratios and their 95% confidence intervals were calculated with logisti
djusted for age and sex. TAA, Thoracic aortic aneurysm; TAD, thoracic aortic
048 The Journal of Thoracic and Cardiovascular Surgery ● Maf 10 minutes at 95°C, 40 cycles of 15 seconds at 92°C, and 1
inute at 60°C.
tatistical Analysis
he frequency distributions of the 3 SNPs were determined for
ach group. The associations between MMP9 polymorphisms and
AA and TAD were estimated with odds ratios (ORs) and their
5% confidence intervals, which were calculated by using uncon-
itional logistic regression models. The ORs were adjusted for age
nd sex. The Pearson 2 test was used to examine differences in
istributions of genotypes between control subjects and an Applied
iosystems white sample set. All analyses were carried out with
tatistical Product and Service Solutions software (Version 12.0;
PSS Inc, Chicago, Ill).
esults
he allelic frequency of MMP98202G was significantly
igher among the patients with TAA and the patients with
AD than among the control subjects (P  .001, Table 3).
dditionally, the proportion of 8202G carriers was sig-
ificantly higher among the patients with TAA (27/28
96%]) and patients with TAD (53/60 [88%]) than among
he control subjects (65/111 [59%], P .001). Patients with
AA were 14 times more likely to have the G allele than
ere control subjects. Patients with TAD were 4 times more
ikely to have the G allele than were control subjects. When
f thoracic aortic aneurysm and thoracic aortic dissection,
Patients with TAA
(n  28)
% Crude OR (95% CI) Adjusted OR (95% CI)
3.6 1.00 1.00
89.3 23.00 (3.00-176.62) 15.42 (1.77-134.18)
7.1 6.13 (0.52-72.52) 6.81 (0.48-96.87)
96.4 19.11 (2.51-145.68) 13.80 (1.60-119.15)
0.52
ression, with the MMP9 variant genotype AA as the reference group, and
dissection; OR, odds ratio; CI, confidence interval.
of thoracic aortic aneurysm and thoracic aortic dissection,
Patients with TAA
(n  28)
% Crude OR (95% CI) Adjusted OR (95% CI)
75.9 1.00 1.00
24.1
0 0.99 (0.38-2.57) 0.65 (0.19-2.28)
0.13
ession, with the MMP9 variant genotype (GG) as the reference group, andisk o
ic regrisk
c regr
dissection; OR, odds ratio; CI, confidence interval.
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A
CDll patients with TAA and patients with TAD were com-
ined into a single group, their 8202G allele frequency
0.535) was significantly higher than that of the control sub-
ects (0.360, P .001); the adjusted OR for the8202G allele
arriers was 4.87 (95% confidence interval, 2.04-11.64). No
llele or genotype of IVS43G/T or 2003A/G (Q668R) was
ignificantly associated with TAA or TAD (Tables 4 and 5).
The frequency distributions of all 3 MMP9 SNPs in our
ontrol population were not significantly different from those
reviously published for white subjects (8202A/G: 2 
.011, P  .92; IVS43G/T: 2  0.19, P  .67; and
003A/G: 2  0.29, P  .56) by Applied Biosystems. The
inor allele frequencies for the SNPs among the 111 con-
rol subjects were 0.36 for 8202A/G, 0.14 for
VS43G/T, and 0.13 for 2003A/G. These frequencies
ere 0.37, 0.15, and 0.15, respectively, in a separate white
opulation (from the Applied Biosystems sample set,
  45; data from Applied Biosystems, http://www.
ppliedbiosystems.com).
Overall, 9 (82%) of the 11 patients with family histories
f thoracic aortic disease had the 8202G allele. In the
AA group all 4 patients with family histories of aneurysms
ere 8202G allele carriers. In the patients with TAD, 3 of
he 4 patients with family histories of aneurysms and 2 of 3
atients with family histories of dissection were 8202G
llele carriers. The8202G allele was present in the patient
ABLE 3
Patients with TAD
(n  60)
o. % Crude OR (95% CI) Adjusted OR (95% CI)
7 11.7 1.00 1.00
39 65.0 5.13 (2.09-12.59) 4.02 (1.57-10.32)
14 23.3 6.13 (2.09-18.03) 5.19 (1.61-16.74)
53 88.3 5.36 (2.24-12.84) 4.26 (1.70-10.66)
0.56
ABLE 4
Patients with TAD
(n  60)
No. % Crude OR (95% CI) Adjusted OR (95% CI)
45 75.4 1.00 1.00
12 19.7
3 4.9 0.99 (0.48-2.04) 0.86 (0.38-1.92)
0.15The Journal of Thoracicith TAD with aortic rupture but not in the patient with the
uptured TAA.
iscussion
oth TAA and TAD involve progressive weakening of the
ortic wall and are primarily associated with a characteristic
istologic appearance of medial degeneration, historically
escribed as “Erdheim cystic medial necrosis,” in which
here is degeneration and fragmentation of elastic fibers,
oss of smooth muscle cells, and an accumulation of baso-
hilic ground substance.15 The medial degenerative process
n TAA and TAD might be limited to one aortic segment or
ight involve the entire aorta. The role of MMP-9 in aortic
egeneration has stimulated interest in its potential as a
herapeutic target.20-24 The MMP-9 protein plays a major
ole in the maintenance of the aortic wall ECM and, as a
egrading enzyme, is critical to arterial wall remodeling.
hen MMP-9 is overproduced, increased elastolytic activ-
ty can result in a weakened aortic wall that is prone to
xpansion. Additionally, MMP-9 can act synergistically
ith MMP-1 to degrade interstitial collagens. These mech-
nisms might explain the association between MMP-9 over-
xpression and abdominal aortic aneurysm formation.25-30
pregulated MMP-9 synthesis has also been reported in
atients with thoracic aortic pathology.10-12
Patients with TAA or TAD
(n  85)
No. % Crude OR (95% CI) Adjusted OR (95% CI)
8 9.4 1.00 1.00
63 74.1 7.25 (3.14-16.74) 4.96 (2.04-12.07)
14 16.5 5.37 (1.89-15.28) 4.52 (1.42-14.37)
77 90.6 6.81 (3.00-15.47) 4.87 (2.04-11.64)
0.54
Patients with TAA or TAD
(n  85)
No. % Crude OR (95% CI) Adjusted OR (95% CI)
64 75.6 1.00 1.00
18 20.9
3 3.5 0.97 (0.51-1.87) 0.78 (0.36-1.67)
0.14and Cardiovascular Surgery ● Volume 131, Number 5 1049
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1
A
CDPolymorphisms are DNA sequence variants that are
resent in at least 1% of the population when the variant is
rst observed. SNPs, locations on a DNA sequence where a
ingle base varies among persons, are the most common
equence variations in the human genome and occur in
bout 1 in every 1000 bases. These SNPs can occur in both
oding and noncoding regions of DNA, producing varying
esults. Because of the degeneracy of the genetic code, not
ll SNPs have deleterious effects; however, SNPs in coding
egions might change the amino acids within proteins,
hereby reducing DNA binding, catalytic activity, and
eceptor-ligand contact. Likewise, SNPs in noncoding re-
ions (ie, 5= untranscribed regions, 3= untranscribed regions,
nd introns) can affect RNA processing, stability and trans-
ation; SNPs in the 5= untranscribed region might also affect
ranscription.31
In the present study we examined the relative frequency of
SNPs in the MMP9 gene among white patients with and
ithout TAA or TAD. We chose these 3 SNPs because of their
otential to affect MMP-9 production and function. The
8202A/G SNP, which was overrepresented among the pa-
ients with TAA and the patients with TAD, occurs in the 5=
ntranscribed region of the MMP9 gene that might have an
nhancer element that increases MMP9 transcription, resulting
n high lifetime MMP-9 levels that can increase susceptibility
o TAA and TAD. Alternatively, this SNP might result in loss
f a repressor, thereby increasing MMP9 transcription. It is
lso possible that the 8202A/G variant is in linkage disequi-
ibrium with functional variants at other sites that might di-
ectly regulate MMP-9 expression. Enhancer-repressor ele-
ents are normally located upstream of the core promoter
f a gene, although this needs to be shown experimentally
or each individual SNP and gene. The IVS43G/T SNP
ccurs at the third base of the fourth intron and therefore has
he potential to influence the RNA splicing process. The
003A/G SNP is a nonsynonymous SNP (ie, an SNP whose
forms produce different amino acids) in the coding region
hat can cause a glutamine-to-arginine substitution at the 668th
mino acid (Q668R) of the MMP-9 protein, potentially
ABLE 5. 2003A/G (Q668R) genotypes, their association w
issection, and A allele frequencies in patients and contr
enotype
Control subjects
(n  111)
No. % No.
G 84 75.7 21
G 25 22.5 7
A 2 1.8 0
allele frequency 0.13
dds ratios and their 95% confidence intervals were calculated with logis
nd adjusted for age and sex. TAA, Thoracic aortic aneurysm; TAD, thoraffecting the protein’s function. Our results, however, sug- t
050 The Journal of Thoracic and Cardiovascular Surgery ● Maest that neither IVS43G/T nor 2003A/G is associated
ith TAA or TAD.
Like all genetic polymorphisms, SNPs can predetermine
he susceptibility of the allele carrier to certain diseases.
owever, in most situations, the functional effect of an SNP
epends on the presence of an environmental trigger. Be-
ause of the interdependence of genetic and environmental
actors, a genetic defect might never manifest itself pheno-
ypically if the carrier is never exposed to a specific trigger.
or example, the 27th repeat polymorphism in the endothe-
ial nitric oxide synthase gene contributes to the risk of
yocardial infarction, although only in smokers.32 Addi-
ionally, different alleles might respond differently to the
ame environmental condition (eg, inflammation), so that
ach exposed individual’s risk of a given disease phenotype
s determined by the particular allele the individual carries.
he relationship between MMP9 polymorphisms and envi-
onmental factors in thoracic aortic disease will require
nvestigation.
Traditionally, SNPs have been identified through the
ecognition of restriction enzymes that digest specific short
NA sequence spans of 4 to 6 bp. When one or more
ucleotides are changed or mutated, either the existing
estriction enzyme recognition site is abolished or a new one
s created. Genomic regions are normally amplified with
CR and digested with a specific restriction enzyme, and the
nd product is resolved in electrophoresis. Different alleles
re determined by different nucleotide lengths after diges-
ion. However, of the increasing number of SNPs that have
een identified with direct sequencing techniques, not all
nvolve changes that can be detected by means of the
estriction enzymes currently in use.
The probe-based direct genomic amplification approach
ircumvents this limitation. Taqman SNP analysis uses the
= exonuclease activity of DNA Taq polymerase and the
uenching effects of specific fluorescent dyes to determine
he relative frequency of each allele within an individual
enome.
An important limitation of our study was the nature of
the risk of thoracic aortic aneurysm and thoracic aortic
bjects
Patients with TAA
(n  28)
% Crude OR (95% CI) Adjusted OR (95% CI)
75.9 1.00 1.00
24.1
0 1.04 (0.40-2.71) 0.68 (0.19-2.41)
0.13
gression, with the MMP9 variant genotype (GG) as the reference group,
ortic dissection; OR, odds ratio; CI, confidence interval.ith
ol su
tic rehe control population, which consisted of patients initially
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A
CDelieved to have heart disease. Although the control pa-
ients’ angiograms were unremarkable and their ascending
ortic diameters were within normal limits, we cannot rule
ut the possibility that these patients might have had iso-
ated aneurysms at other segments of the aorta. Because
ndividuals with asymptomatic aortic pathology are fre-
uently regarded as healthy, it is almost impossible to obtain
group of volunteers or healthy donors who are all con-
rmed free of TAA and TAD unless complete thoracic
ortic imaging is conducted. Another limitation of this study
as that only basic demographic information was collected
rom the control patients, and thus we had no information
bout the control subjects’ family histories of TAA or TAD.
Because our investigation is a genetic association study,
ur findings do not confirm a functional role for the
8202G allele in MMP-9 expression; functional investiga-
ion of this allele is warranted. Elucidating the molecular
echanisms of AG-allele–mediated MMP-9 regulation will
equire many experiments to identify transcription factors,
haracterize their transactivating effects with the promoter
r other enhancer, generate recombinant vectors, and so
orth. We have initiated experiments regarding the func-
ional characterization of MMP9 polymorphisms.
In summary, our study found that the MMP9 8202A/G
olymorphism was associated with TAA and TAD in a white
opulation. Although further studies are needed to prospec-
ively analyze the association between the 8202A/G geno-
ypes and the incidence of thoracic aortic disease and to
valuate the potential causal relationships between them,
hese results support the hypothesis that MMP9 plays a role
n the pathogenesis of TAA and TAD. The discovery of
isease-associated SNPs might ultimately refine the assess-
ent of TAA and TAD risk in individual patients and provide
rognostic information to guide patient care. Our ultimate goal
s to create a genetic test that will allow physicians to screen
ndividuals for their susceptibility to TAA and TAD by ana-
yzing their DNA for specific SNP patterns.
We thank Stephen N. Palmer, PhD, ELS, for providing editorial
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